The acetylated IGF2BP3‐PCK2‐SAM‐m6A axis sustained higher expression of PCK2 and NRF2, reinforced the antioxidant defense, and promoted lenvatinib resistance in HCC. The gene discussed is IGF2BP3; the disease is hepatocellular carcinoma.